**Toxicoderma in a child as a complication after a bedbug bite**

For citation: Child’s Health. 2022;17(4):199-203. doi: 10.22141/2224-0551.17.4.2022.1517

**Abstract.** Background. Toxic dermatitis is an adverse skin reaction caused by various factors. Analysis of clinical cases helps identify problems, and plan future studies, which can change the understanding of the consequences of the disease. The purpose was to improve the diagnosis of allergic dermatoses in children, to analyze clinical and paraclinical features of their course, and biomarkers of sensitization to allergens. Materials and methods. Presentation of a case study was a basis for discussion, as well as literature search in the MEDLINE and Scopus databases. The study was conducted in accordance with the principles of the Declaration of Helsinki. The research protocol was approved by the ethics committee of the institution mentioned in the work. Informed consent of child’s parents was obtained for the research. Results. The clinical picture of toxic dermatitis is very diverse, almost any type of lesion can occur, and often the clinical symptoms are very similar to skin diseases that are not caused by various toxic agents. The most common clinical symptom is maculopapular exanthema. Conclusions. The peculiarity of the presented case is toxicoderma in a child after a bedbug bite. It is important to establish the correct diagnosis of toxic dermatitis, identify toxic agent, stop its exposure and treat the adverse reaction, usually with antihistamines and corticosteroids.

**Keywords:** children; allergy; allergic dermatoses

**Introduction**

Recently, in most countries of the world, there is a significant increase in allergic skin diseases — allergodermatoses, especially in children. Analysis of clinical cases helps identify problems, and plan future studies, which can change the understanding of disease consequences.

**Clinical case.** A 9-year-old boy was urgently admitted to the Ternopil Regional Children’s Clinical Hospital with complaints of an increase in body temperature to subfebrile numbers, itching, rashes on the skin of the back, and scratches on the upper and lower limbs.

**Medical history.** The patient has been sick for the past 2 weeks when the above complaints appeared and hospitalized in Chortkiv Central Hospital.

History of life: from the first pregnancy and the first childbirth. The child was not sick during the newborn period. Previous diseases: acute respiratory infection under the age of one year.

Allergic anamnesis: not aggravated. Hereditary history: not burdened. Preventive vaccinations: not received according to age. History: during last 21 days, no bowel disorders were detected. There were bedbug bites in the apartment where the child lives.

**Objective status.** General condition of the child was of medium severity due to intoxication syndrome. Consciousness is clear. The skin is pale, with a rash with scratches and bloody crusts. Subcutaneous adipose tissue is satisfactorily developed. Breathing through the nose is difficult. Visible mucous membranes are pale pink, and clean. Throat — moderate hyperemia. The tongue has gray coating on it. Lymph nodes are not enlarged.

Percussion limits of relative cardiac dullness are not common. Auscultatively, the activity of the heart is rhythmic, tones are sonorous. Heart rate — 98 bpm, BH — 20, body temperature — 37 °C. Auxiliary muscles do not participate in the act of breathing. Pulmonary sound percussively...
over the lungs. Vesicular breathing over the lungs by auscultation. The abdomen is not painful during superficial palpation. Liver +1.5 cm, is not painful, the edge is rounded. The spleen is not enlarged.

**Status localis.** Complaints about the appearance of rashes on the child’s back, arms, and legs, an increase in body temperature to febrile numbers. The skin is pale with traces of scratches on the hands and feet. In the lumbar region, there is a confluent maculopapular rash.

General blood test upon admission revealed leukocytosis with neutrophilia (Table 1). In the immunogram, an increase in immunoglobulin E to 600 IU/ml was observed (with reference standards < 90.0 IU/ml).

Coprogram (06.09.21): the stool is loose, dark brown, mushy, with remains of undigested food. Muscle fibers are not changed, 3–4 in the field of view. Significant amount of plant fibers is not digested. A moderate amount of mucus — 1–2 in the field of view. Leukocytes — 0–1.

Ther was moderate amount of fungi elements; helminth eggs were not found. A scraping for enterobiasis (02.09) — negative. General analysis of urine was without pathological changes.

**Dermatologist consultation** (09.02.21). The skin and mucous membranes of the oral cavity were examined. Diagnosis: toxicoderma of the skin of the back and lumbar region, maculopapular form, draining of medium severity.

**Table 1. Indicators of the patient’s general blood analysis in dynamics**

| Date     | Erythrocytes, 10¹²/L | Hb, G/l | Leukocytes, 10⁹/L | Eosinophils, % | Bands, % | Segments, % | Lymphocytes, % | Monocytes, % | ESR, mm/hr | Trombocytes, 10⁹/L |
|----------|----------------------|---------|-------------------|----------------|----------|------------|----------------|-------------|-----------|------------------|
| 01.09.21 | 3.29                 | 102     | 11.5              | –              | 10       | 75         | 10             | 5           | 12        | –                |
| 02.09.21 | 4.4                  | 121     | 12                | 1              | 10       | 60         | 26             | 3           | 30        | 321              |
| 06.09.21 | 4.41                 | 127     | 6.76              | 2              | 4        | 64         | 22             | 8           | 7         | 333              |

**Note:** ESR — erythrocyte sedimentation rate.

**Table 2. Biochemical blood analysis**

| Indicator, units | 02.09.21 | Reference standards |
|------------------|----------|---------------------|
| Glucose, mmol/l  | 5.79     | 3.33–5.89           |
| Total protein, g/l| 76.3     | 60–80               |
| Total bilirubin, μmol/l | 7.4 | 17               |
| Cholesterol, mmol/l | –     | < 5.2               |
| Alanine aminotransferase, IU/l | 15 | 16.13             |
| Aspartate aminotransferase, IU/l | 13.7 | 33.99              |
| Creatinine, μmol/l | 33.3     | 73.32              |
| Urea, mmol/l | 3.73     | 1.79–6.43           |
| Amylase, U/l | 20.7     | 12.16               |
| Ca²⁺ (ionized), mmol/l | 2.67 | 1.15               |
| K, mmol/l | 4.48     | 4.2                 |
| Na, mmol/l | 133.9    | 128.5               |
| C-reactive protein, mg/l | 10.59 | < 5               |

Recommendations: continue treatment according to medical prescriptions. Topical emollients with constitutionally dry skin and monitoring of this rash.

**Clinical diagnosis:** toxicoderma, maculopapular form, draining of medium severity.

Treatment was carried out with loratadine, enterosgel, infusion therapy, and local emulsifiers.

The boy was discharged home with improvement.

**Discussion**

Most cases of toxicoderma proceed by the mechanism of an immediate allergic reaction after acquired sensitization of the body or in connection with idiosyncrasy (congenital intolerance). At the same time, unlike allergic contact dermatitis, the toxicoderma factor does not contact with the patient’s skin. Allergic contact dermatitis is a cell-mediated hypersensitivity reaction of the skin and is usually induced by a non-viral factor or xenobiotic (hapten) that is absorbed into the skin and reacts with self-proteins, leading to an immune response [1, 2].

The pathogenesis of toxicoderma simultaneously combines toxic and allergic components, which causes the development of various lesions on the skin, mucous membranes, vascular system, and internal organs [3].

Entering the body in various ways, a toxin is absorbed into the blood and blood vessels and reaches the skin. The basis of toxicoderma pathogenesis is an allergic reaction as a manifestation of the sensitizing effect of an exogenous sub-
stance (allergen). Thus, with toxicoderma, the action of the allergen on the skin occurs as if from inside the body. As a result of the emergence, modern dermatology distinguishes 4 etiological groups of toxicodermas: medicinal, alimentary, professional, and autotoxic.

Symptoms of toxicoderma

The clinical picture is characterized by a wide variety of forms. Rashes on the skin can be papular, vesicular, erythematous, urticarial, and papulo-vesicular. Damage to the mucous membrane of the oral cavity and lips can be vesicular-erosive, catarrhal, or hemorrhagic. In some cases of toxicoderma, not only the mucous membrane of the mouth is affected, but also the mucous membrane of the genitals, urethra, and anal region of the rectum. Rashes on the skin and mucous membranes in toxicoderma are usually accompanied by various subjective sensations of the patient: tension, burning, soreness, and itching of the skin in the affected areas. The basis for establishing a diagnosis of toxicoderma is its characteristic clinical picture.

Depending on the prevalence of clinical manifestations, fixed and widespread forms of toxicoderma are distinguished. A fixed form of toxicoderma in most cases is manifested by the appearance on the skin of several round erythematous spots with a diameter of 2–3 cm. Over time, the spots may acquire a brown color, and bubbles form in the middle of some of them. Elimination of the further entry of the allergen into the body leads to the disappearance of a fixed toxicoderma within 10 days.
**Diagnostic algorithm**

1. History collection is aimed at identifying the causative factor of the disease. In case of toxicoderma, skin allergy tests often do not give results. The use of provocative samples with a possible allergen is associated with the risk of developing a severe form of toxicoderma [4].

Skin prick tests and determination of specific IgE antibodies are used to diagnose IgE-mediated allergy of the immediate type, which mainly causes symptoms from the respiratory tract. These tests are rarely indicated for the diagnosis of skin diseases (e.g., contact urticaria, severe atopic dermatitis in young children, and food allergies). Skin (patch) tests are used to diagnose delayed contact allergy (allergic contact dermatitis).

2. Only in vitro tests can be used to determine the causative substance: the reaction of degranulation of basophils, blast transformation of lymphocytes, agglomeration of leukocytes, and others.

3. To rule out the infectious nature of the rashes, bacteriological examination of the material, skin scrapings for pathogenic fungi, microscopy of smears for pale treponema, rapid plasma reagin test for syphilis should be performed.

4. In case of a widespread form of toxicoderma, a coagulogram and a study of the main biochemical parameters in the blood and urine analysis are performed. In case of damage to internal organs, consultation with a cardiologist, gastroenterologist, nephrologist may be necessary.

5. Electrocardiography, echoencephalography, ultrasound of abdominal organs and liver, ultrasound or computed tomography of kidneys were carried out.

6. Specific IgE antibodies were determined similarly to spot tests in the study of immediate (IgE-mediated) allergy. The level of specific antibodies to allergens is measured in the blood serum of patients. It is possible to perform group tests (usually as a screening) containing several allergens (for example, a group of allergens from dust), or to determine antibodies to individual allergens.

The diagnosis of toxicoderma according to the etiological factor distinguishes medicinal, vaccine, food, autointoxication forms, three degrees of severity (mild, moderate, severe), and the prevalence of rashes (localized, widespread, diffuse). According to the morphological elements of rashes, toxicoderma can be spotted, papular, maculopapular, urticarial, vesicular, bullous, nodular, pigmented, purpuric, bullous-hemorrhagic [2].

The clinical classification of toxicoderma according to the level of knowledge about the correct diagnostic algorithm is important to establish the correct diagnosis of toxic dermatitis, identify a toxic agent, stop its influence and treat the adverse reaction, usually with antihistamines and corticosteroids that help stabilize the child’s condition, will contribute to the rapid regression of exanthema with enanthema and decrease the development of complications [11].

**Conclusions**

The peculiarity of the presented case is toxicoderma in a child following a bugbite complicated by allergic contact dermatitis. The treating physician needs to be alert to establish the correct diagnosis of toxic dermatitis, identify a toxic agent, stop its influence and treat the adverse reaction, usually with antihistamines and corticosteroids that help stabilize the child’s condition, will contribute to the rapid regression of exanthema with enanthema and decrease the development of complications [11].

**References**

1. Dragó F, Puolino S, Rebona A, et al. The challenge of diagnosing atypical exanthems: a clinico-laboratory study. J Am Acad Dermatol. 2012 Dec;67(6):1282-1288. doi:10.1016/j.jaad.2012.04.014.

2. Martin SF, Eser PR, Weber FC, et al. Mechanisms of chemical-induced innate immunity in allergic contact dermatitis. Allergy. 2011 Sep;66(9):1152-1163. doi:10.1111/j.1398-9995.2011.02652.x.

3. Bourrín JL. Toxicoderma. EMC-Dermatología. 2017;51(4):1-13. doi:10.1016/S1761-2896(17)7052-7.
Токсичний дерматит — це побічна реакція шкіри, спричинена різними факторами. Аналіз таких реакцій шкіри визначає, що не викликані різними токсичними агентами. Найбільш часті симптоми дуже схожі на такі при захворюваннях шкіри, що не викликані різними токсичними агентами. Найбільш частим клінічним симптомом є плямисто-папульозна екзантерма.

**Висновки.** Клінічна картина токсичного дерматиту дуже різноманітна, може виникнути практично будь-який вид ураження, часто клінічні симптоми дуже схожі на такі при захворюваннях шкіри, що не викликані різними токсичними агентами. Найбільш частим клінічним симптомом є плямисто-папульозна екзантерма. Висновки. Особливістю описаного випадку є токсикодермія в дитинні після укусу клопа. Важливо встановити правильний діагноз токсичного дерматиту, ідентифікувати токсичний агент, припинити його вплив і лікувати побічні реакції, як правило, антигістамінними препаратами та кортикостероїдами.

**Ключові слова:** діти; алергія; алергічні дерматози

**Information about authors.**

Svetlana Nykytyuk, MD, PhD, Department of Children’s Diseases with Pediatric Surgery, I. Horbachevsky Ternopil National Medical University, Ternopil, Ukraine; e-mail: androx@tdmu.edu.ua; levenetsss@tdmu.edu.ua

Sofiya Levenets, MD, PhD, Associated Professor, Department of Children’s Diseases with Pediatric Surgery, I. Horbachevsky Ternopil National Medical University, Ternopil, Ukraine; e-mail: levenetsss@tdmu.edu.ua

Z.Ya. Borys, Doctor, Dermatologist of the Infectious-Diagnostic Department, Ternopil Regional Children’s Hospital, Ternopil, Ukraine; e-mail: Zorvik@ukr.net

**Conflict of interests.** Authors declare the absence of any conflicts of interests and own financial interest that might be construed to influence the results or interpretation of the manuscript.

**Authors’ contributions.** Svetlana Nykytyuk — diagnostic procedures, clinical diagnosis, treatment decisions, writing the manuscript, data acquisition, collection and assembly of the articles/published data, and their inclusion and interpretation in this review; Sofiya Levenets — diagnostic procedures, clinical diagnosis, treatment decisions, data acquisition, collection and assembly of the articles/published data, and their inclusion and interpretation in this review; Z.Ya. Borys — writing the manuscript, data acquisition, collection and assembly of the articles/published data, and their inclusion and interpretation in this review. All authors contributed to the critical revision of the manuscript for valuable intellectual content. All authors have read and agreed to the published version of the manuscript.

**Compliance with ethics requirements.** The authors declare that all the procedures and experiments of this study respect the ethical standards in the Declaration of Helsinki 1975, as revised in 2008(S), as well as the national law. Informed consent was obtained from the patient included in the study.